通貨 / NRIX
NRIX: Nurix Therapeutics Inc
11.88
USD
0.16
(1.33%)
NRIXの今日の為替レートは、-1.33%変化しました。日中、通貨は1あたり11.78の安値と12.33の高値で取引されました。
Nurix Therapeutics Incダイナミクスに従います。リアルタイムの相場は、市場の変化に迅速に対応するのに役立ちます。 異なる時間枠に切り替えることで、為替レートの傾向とダイナミクスを分、時間、日、週、月単位で監視できます。この情報を使用して、市場の変化を予測し、十分な情報に基づいて取引を決定してください。
- M5
- M15
- M30
- H1
- H4
- D1
- W1
- MN
NRIX News
- Investing Nurix therapeutics (NRIX) CSO Hansen sells $51k in stock
- Investing Nurix Therapeutics’ ring sells $46k in stock to cover tax obligations
- Investing Nurix Therapeutics CFO van Houte sells $51,695 in shares
- Investing Morgan Stanley lowers Nurix stock price target to $16 on higher spend
- TipRanks Top 3 Trending Stocks, According to Analysts – 7/11/2025 - TipRanks.com
- Investing Stifel maintains Buy rating on Nurix stock, sees $4.5B peak sales potential
- Investing Nurix stock price target lowered to $26 by UBS on increased OpEx
- Investing Goldman Sachs initiates Nurix stock with Buy rating, $182 price target
- Investing Stifel reiterates Buy rating on Nurix stock, sees $4.5B peak sales potential
- Investing Nurix earnings beat by $0.19, revenue topped estimates
- Investing Nurix Therapeutics beats quarterly expectations on strong collaboration revenue
- Investing Nurix stock maintains Buy rating at H.C. Wainwright on positive BTK degrader data
- Seeking Alpha Tracking Baker Brothers Portfolio – Q1 2025 Update
- Investing Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Investing Nurix stock price target reiterated at $30 by UBS on positive trial data
- Investing Nurix stock price target raised to $28 from $27 at RBC Capital
- Investing Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chroni
- Investing Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congr
- Investing Stifel analysts maintain Buy rating on Nurix stock after SNY deal
- Investing UnitedHealth, Biontech lead Monday’s market cap stock movers
- Investing Sanofi extends license option with Nurix’s STAT6 program
- Benzinga Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout - Nurix Therapeutics (NASDAQ:NRIX), Blueprint Medicines (NASDAQ:BPMC), Sanofi (NASDAQ:SNY)
- Investing Nurix secures additional $15 million from Sanofi license deal
- Investing Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference
1日のレンジ
11.78
12.33
1年のレンジ
8.18
29.56
- 以前の終値
- 11.89
- 始値
- 12.04
- 買値
- 11.88
- 買値
- 12.18
- 安値
- 11.78
- 高値
- 12.33
- 出来高
- 2.183 K
- 1日の変化
- -1.33%
- 1ヶ月の変化
- 4.30%
- 6ヶ月の変化
- -38.79%
- 1年の変化
- -46.00%
31 7月, 木曜日
11:30
USD
- 実際
- 期待
- 前
- 47.999 K
11:30
USD
- 実際
- 期待
- -68.3%
- 前
- -1.6%
12:30
USD
- 実際
- 期待
- 0.4%
- 前
- 0.2%
12:30
USD
- 実際
- 期待
- 2.6%
- 前
- 2.7%
12:30
USD
- 実際
- 期待
- 0.2%
- 前
- 0.1%
12:30
USD
- 実際
- 期待
- 2.3%
- 前
- 2.3%
12:30
USD
- 実際
- 期待
- 0.2%
- 前
- -0.1%
12:30
USD
- 実際
- 期待
- 0.7%
- 前
- -0.4%
12:30
USD
- 実際
- 期待
- 0.0%
- 前
- -0.3%
12:30
USD
- 実際
- 期待
- 0.9%
- 前
- 0.9%
12:30
USD
- 実際
- 期待
- 1.0%
- 前
- 1.2%
12:30
USD
- 実際
- 期待
- 0.7%
- 前
- 0.8%
12:30
USD
- 実際
- 期待
- 224 K
- 前
- 217 K
12:30
USD
- 実際
- 期待
- 1.966 M
- 前
- 1.955 M
12:30
USD
- 実際
- 期待
- 222.299 K
- 前
- 224.500 K
13:45
USD
- 実際
- 期待
- 42.4
- 前
- 40.4
14:00
USD
- 実際
- 期待
- 2.3%
- 前
- 2.0%
14:30
USD
- 実際
- 期待
- 2 B
- 前
- 23 B
15:30
USD
- 実際
- 期待
- 前
- 4.245%
15:30
USD
- 実際
- 期待
- 前
- 4.265%